Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.…
Regentis Signs Exclusive Distribution Agreement with AMI Technologies to Commercialize GelrinC(R) in Israel
Regentis Biomaterials (NYSEAMERICAN: RGNT) is listed on NYSE American, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector.
The shares were at 0.7186 USD on 20 November 2026. Its 52-week range is 0.7123 USD to 15.50 USD, and it trades at the bottom of that range.
Its market capitalisation is 5.05M USD.
Regentis Biomaterials reports return on equity of -287.7% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 8.92M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.
No upcoming events tracked.